Creyon has three active wholly-owned products in its pipeline. Our lead neuromuscular program is advancing toward clinical development, positioning Creyon among the few RNA-focused private biotechnology companies transitioning from preclinical discovery to human studies.
Crossing the Blood–Brain Barrier with RNA Therapeutics
Our CNS program has established proof of concept in animals, indicating that it can shuttle nucleic acid drugs across the blood-brain-barrier (BBB) to reach disease-relevant targets in the brain. Creyon’s proprietary platform integrates state-of-the-art aptamer-delivery technology (structured nucleic acids that selectively bind target tissues) with NucleIQ™, our patented computational engine for designing and optimizing nucleic acid drug payloads.
Aptamers + NuclelQ™ = Better Together
Creyon has built the industry’s first and only AI-powered nucleic acid engineering engine (NucleIQ) that enables a more efficient and derisked approach to designing safe and active nucleic acid therapies by leveraging our proprietary, purpose-built pharmacology datasets and insights into nucleic acid chemistry to create pioneering AI/ML predictive models for drug candidate safety and activity. This coupled with a highly precise targeting approach utilizing its aptamer-delivery technology to potentially improve the benefit-risk advantage of therapies in Creyon’s pipeline.
Our Investors
